Study aim: Effect of Spirulina as a nutritional supplement and drug in Covid-19 patients Design: clinical trial with control group , with parallel groups , double-blind , randomized , phase 2on 100 (...) with positive covid-19 PCR referred to Imam Reza hospital in Tabriz was randomly admitted to one of the

Study aim: Evaluation of methylene blue administration on mortality of patients with acute respiratory distress syndrome caused by Covid disease 19 Design: A randomized, phase 3, clinical trial with parallel groups and without blinding is performed on 130 patients. Simple randomization is done using

Study aim: The effect of Royal Jelly Capsule on reducing the side effects of methylprednisolone treatment in COVID-19 patients Design: In this study, individuals are divided into two groups of (...) injections are recorded. Settings and conduct: 60 patients with Covid-19 with positive PCR test and lung

Study aim: The aim of this study is to compare the effect of the bromhexine hydrochloride solution for inhalation and placebo on the improvement of respiratory condition in patients with COVID-19 by focusing on the severity of the cough. Design: A double-blinded randomized, placebo-controlled clinical

covid-19 based on a previous positive PCR;Treatment of active CMV infection;History of receiving

Study aim: Determining the effectiveness of respiratory-physical exercises on fatigue and quality of life of nurses caring for COVID-19 patients in the intensive care unit Design: This is a clinical trial study in which samples are selected by convenience sampling method and then divided into two

Study aim: The effect of curcumin supplementation on clinical symptoms, acute phase reactants and cytokine interleukin 6 in patients with new Covid-19 admitted to hospital Design: A double-blind clinical trial study with placebo Settings and conduct: This study is a double-blind randomized clinical trial

Study aim: Evaluation the effect of ZAX.1400.C01 on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients hospitalized Design: A triple-blind (...) : 1. Definitive diagnosis of COVID-19 2. Age between 18 to 65 years 3. Both sexes (male and female) 4

vaccine. Participants with a positive result were included in the prior COVID-19 infection group and had (...) were included in the no-prior COVID-19 infection group and had antibody levels measured on day 21 after (...) opinion at the Regional Medical Chamber in Gdansk KB-4/21). Main outcome variables: Prior COVID-19

Study aim: The effect of chitosan supplementation on clinical symptoms in patients with COVID-19 Design: The 80 eligible participants in the phase 2 clinical trial are randomly assigned to either the chitosan group or the placebo group. Patients will be divided into 2 equal groups using the block

Study aim: Effects of low-load resistance training with blood-flow restriction on function, strength and thickness of the quadriceps muscles in COVID-19 survivors after recovery Design: Randomized (...) used for randomization. Settings and conduct: The COVID-19 survivors who are eligible for this study

Study aim: Determination of the effect of silymarin on rhodsivider-induced hepatotoxicity in patients with COVID-19 admitted to Shahrekord hospitals Design: Clinical trial with control group, with parallel groups, double-blind, randomized, on 70 patients. Excel software rand function was used for

Study aim: Determining the effect of acobsen relaxation application on anxiety and job stress of nurses caring for Covid 19 patients Design: A community-based, pragmatic, control group clinical trial (...) patients with Covid 19; Having a smart phone with Android operating system No entry conditions

Study aim: Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients: A double-blind randomized controlled trial, phase II Design: Randomize double blind clinical trial, with control group, with a sample size of 60 people, with parallel groups, Phase 2 of Clinical trial

Study aim: Comparison of the effectiveness of Hydroxychloroquine versus Clarithromycin in Patients with Persistent dyspnea and cough at the end of acute phase COVID-19 Design: The study is a clinical trial that is performed with a Parallel design as a pilot in three groups and each group contains 15

Study aim: Effects of Tocilizumab‎, interferon-gamma and vitamin C on serum ferritin, LDH, CPK, CRP lung tissue, heart, lymphocytes, neutrophils, PCO2, and serological tests. Design: The randomized clinical trial consists of a control group,two parallel groups,non blinded,and phase 2. All the 60 patients are systematically assigned to random groups. Randomization will be conducted by SAS software. Settings and conduct: This clinical trial will be undertaken at Ahar Hospital, in East Azarbaijan Province, Iran, under the supervision of Tabriz University of Medical Sciences. It is approved by the ethics committee of TUOMS. In all patients, the serum levels of ferritin, LDH, CPK,CRP,IL1,IL6,IL18,TNFa should be significantly higher, and pulmonary involvement should be evident in the CT scan. In addition to the routine medication, Group 1 will receive the Tocilizumab‎ Vial. Group 2 will receive interferon-gamma and Vitamin C besides the usual medication, and the control group will receive only the routine medication. All patients will be monitored for two weeks. In the first and last days of treatment, a CT scan will be performed for patients to examine the lungs and heart. Blood samples will also be taken to check blood constituents (neutrophils, lymphocytes, ferritin, ALT, AST, VBG). In the next step, PCO2 will be measured. All of the above steps will be repeated on days 3-7-10, and 14. Participants/Inclusion and exclusion criteria: Inclusion criteria: Lack of a specific clinical disease, 18 to 65 years of age, no pregnancy, symptoms of cytokine storm, Exclusion criteria: An underlying illness, under 18 and over 65 years of age, pregnancy Intervention groups: 1: Tocilizumab‎ along with routine medications, 2: interferon-gamma and Injectable vitamin C along with routine medications, 3: Only routine medications Main outcome variables: Ferritin serum LDH CPK CRP IL1,IL6,IL18,TNFa

Study aim: Determining the effectiveness of Ivermectin in the treatment of Covid-19 infection in hospitalized patients in Mazandaran educational hospitals in 2020 Design: Clinical trial with control group (...) is allocated. Participants/Inclusion and exclusion criteria: Patients with suspected Covid-19

Study aim: Determining the effect of combined herbal medicines on Polium and Hisspus on the prevention of coronavirus in healthy people exposed to coronavirus patients Design: Clinical trial with control group, with parallel groups, three-way blind, randomized, phase 3 on 300 individuals. RAS software was used for randomization. Settings and conduct: This study is a three-way blind clinical trial in which the target population is high-risk families exposed to the coronavirus in Tabriz. Two herbal medicines, polioum, hisspus and placebo, will be used in three intervention groups at a daily dose of 10 cc for 20 days. Medicines and placebo are prepared in similar bottles of 500 ml. Blinding is done for the researcher, the patient, and the analyzer.Tracking of the status of people taking the drug will be done every five days by phone call and filling out the information form about the occurrence or non-occurrence of coronary artery disease symptoms and the possible occurrence of side effects caused by drug use. The research results will be statistically analyzed using SPSS version 21 / software. Participants/Inclusion and exclusion criteria: Inclusion criteria: 1) High-risk people exposed to the coronavirus 2) Age 7 years and older 3) Having a conscious consent form signed to participate in the study 4) Lack of simultaneous participation in other clinical trials Exclusion criteria: 1) People with suspicious, probable or definite symptoms of the disease and need hospitalization or receiving Corona medication on an outpatient basis and their families 2) Pregnant women 3) Breastfeeding women 4) Having liver or kidney failure Intervention groups: Intervention groups include three groups receiving Polium, Hisspus, and placebo. Main outcome variables: The incidence of dry cough, fever, sore throat, shortness of breath, shivering, proprietary testing positive for coronavirus

Study aim: Evaluation and presentation of an uncomplicated herbal medicine and a simple and limited treatment in controlling and reducing the outward and vital signs of patients with coronavirus. Design: 1. A placebo group that uses common medicines and boiled water. 2. A group of patients who use only common medications. 3. A group of patients who use common medications with the extract of the plant under study Settings and conduct: Ali Asghar hospital; Strong clinical diagnosis of patients based on lung scan sciatica. This procedure is quick and easy, with a 98% chance of success, however, it is still a definitive test with RT PCR testing. Therefore, both factors will be evaluated for the final diagnosis and confirmation of the disease. CBC, CRP, ESR, blood pressure, heart rate and blood oxygen concentration will also be assessed and recorded for patients. Participants/Inclusion and exclusion criteria: Positive corona testing or confirmation of symptoms such as fever, muscle and bone pain, cough and sore throat. In a paraclinical study, platelet counts, white blood cell counts, and ESR and CRP levels were significantly increased. In the blood gas test, the saturation of O2 is less than 93%. In contrast, patients with a history of allergies to herbal remedies or those with liver, kidney, heart, and vascular insufficiency will be excluded from the study. Patients with diabetes or other endocrine diseases, as well as people who are constantly under the control and treatment of neuroleptic drugs, are not included in the study. Normally, pregnant and lactating mothers will not be included in the study due to the lack of sufficient evidence on the safety of herbal medicine. Patients who are unable to swallow or have NPO are removed and patients are mechanically ventilated. Intervention groups: 2 groups of drugs and control Main outcome variables: Low production costs, low side effects

: Patients with Covid 19; Conscious consent of the patient. Exclusion criteria: Malignant diseases; Severe

definitive diagnosis of COVID-19, which subsequently develops acute respiratory distress syndrome. COVID-19

included in the study with a definitive diagnosis of COVID-19, which subsequently develops acute respiratory distress syndrome (mild or moderate). COVID-19 patients with severe underlying disease or

Study aim: Determination of the prophylactic effect of hydroxychloroquine on the prevention of covid19 in medical staff in Arak Design: A randomized clinical trial, controlled by 90 people (two equal groups (45 people)) from the health care staff (in Arak city) who are dealing with patients. One group will be given hydroxychloroquine and the other group will be given routine care. Settings and conduct: At the beginning of the study, the conditions will be fully explained to the individuals, the conditions of the drugs will be explained, and people will also be told that they are randomly assigned to one of the two groups and will be reassured. Their information will remain confidential to the researcher and they can be removed from the study at any stage of the study. Participants/Inclusion and exclusion criteria: Inclusion criteria : 1. Have a consent to participate in the study 2. People working in medical centers in Arak 3. Lack of sensitivity to hydroxychloroquine 4. Lack of G6PD disease 5. Lack of porphyria 6. Lack of breastfeeding 7. Not getting pregnant 8. Lack of diabetes, kidney and liver disease, and skin problems Exclusion Criteria: 1- Lack of desire to continue the study 2- Having major side effects Intervention groups: Hydroxychloroquine is a drug that was originally used to prevent and treat malaria. These drugs are known as anti-malarial drugs, and since the ocular side effects of hydroxychloroquine are less than those of chloroquine, most hydroxychloroquine is now prescribed to treat rheumatological diseases. In this study, participants in the intervention group would receive 400 mg of hydroxychloroquine for eight weeks, and those in the control group would receive routine care for diseases. It should be noted that both groups will receive routine care. Main outcome variables: The incidence of the disease and its severity will be compared between the two groups

Study aim: Effect of asafoetida in coronavirus outpatients Design: Randomized, blinded, placebo controlled clinical trial. Effect of asafoetia capsules in 40 patients which have inclusion criteria will be evaluated. Simultanously, 20 patients will take placebo. Medicine and placebo in the same form and package with the alphabetics A and B will be deliverd to physiciana and patients. Patients must take the capsules three times a day for 14 days Settings and conduct: Randomized, blinded, placebo controlled clinical trial will be in mashhad . effect of asafoetida capsules in 40 patients with coronavirus disease which have inclusion criteria will be evaluated. Simultanously 20 patients will take placebo. Medicine and placebo in the same form and package with the alphabetics A and B will be deliverd to physician and patients. The patients must take the capsules three times a day for 14 days Participants/Inclusion and exclusion criteria: Inclusion criteria: The outpatients in quarantine, take medicine, diagnosed for coronavirus disease according to clinic ( fever, cough, myalgia) and paraclinic parameters (lymphopenia, increase CRP). Exclusion criteria: Sensitivity to licorice and it derivatives; below 18 and above 65 years old; hepato, renal or respiratory disorders; take cytotoxic, corticosteroid drugs; nursing or pregnant women Intervention groups: En Effect of asafoetdida capsules in 40 patients (two groups) which have inclusion criteria will be evaluated. Simultanously 20 patients which have inclusion criteria will take placebo. Main outcome variables: Time interval until lymphopenia improves Time interval until CRP normalizes Time interval until clinical symptoms improve (fever, cough and myalgia)

included in the study with a definitive diagnosis of COVID-19, which subsequently develops acute respiratory distress syndrome (mild or moderate). COVID-19 patients with severe underlying disease or